vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Commercial Vehicle Group, Inc. (CVGI). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $154.8M, roughly 1.2× Commercial Vehicle Group, Inc.). On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -5.2%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $8.7M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -10.8%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
WABCO Holdings, Inc. was a U.S.-based provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. In 2007, the Vehicle Control Systems was spun off as WABCO Holdings Inc., an American provider of electronic braking, stability, suspension and transmission automation systems for heavy-duty commercial vehicles. Their products are present in many commercial vehicles such as trucks, buses, trailers and off-highway vehicles but they ...
AVNS vs CVGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $154.8M |
| Net Profit | $-1.3M | — |
| Gross Margin | 47.5% | 9.7% |
| Operating Margin | 1.4% | -1.2% |
| Net Margin | -0.7% | — |
| Revenue YoY | 0.7% | -5.2% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $154.8M | ||
| Q3 25 | $177.8M | $152.5M | ||
| Q2 25 | $175.0M | $172.0M | ||
| Q1 25 | $167.5M | $169.8M | ||
| Q4 24 | $179.6M | $163.3M | ||
| Q3 24 | $170.4M | $171.8M | ||
| Q2 24 | $171.7M | $193.7M | ||
| Q1 24 | $166.1M | $194.6M |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $-7.1M | ||
| Q2 25 | $-76.8M | $-4.8M | ||
| Q1 25 | $6.6M | $-4.3M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $9.5M | ||
| Q2 24 | $1.8M | $-1.6M | ||
| Q1 24 | $-900.0K | $2.9M |
| Q4 25 | 47.5% | 9.7% | ||
| Q3 25 | 48.4% | 10.5% | ||
| Q2 25 | 52.6% | 11.4% | ||
| Q1 25 | 53.6% | 10.5% | ||
| Q4 24 | 54.6% | 8.0% | ||
| Q3 24 | 54.5% | 9.6% | ||
| Q2 24 | 55.7% | 10.6% | ||
| Q1 24 | 57.1% | 11.9% |
| Q4 25 | 1.4% | -1.2% | ||
| Q3 25 | 0.1% | -0.7% | ||
| Q2 25 | -42.6% | 0.5% | ||
| Q1 25 | 6.1% | 0.8% | ||
| Q4 24 | -233.0% | -3.2% | ||
| Q3 24 | 7.0% | -0.6% | ||
| Q2 24 | 3.7% | 0.5% | ||
| Q1 24 | 2.4% | 2.3% |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | -4.6% | ||
| Q2 25 | -43.9% | -2.8% | ||
| Q1 25 | 3.9% | -2.5% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | 5.5% | ||
| Q2 24 | 1.0% | -0.8% | ||
| Q1 24 | -0.5% | 1.5% |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-1.66 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.04 | $-0.05 | ||
| Q1 24 | $-0.02 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | $104.9M |
| Stockholders' EquityBook value | $778.2M | $133.4M |
| Total Assets | $1.1B | $391.7M |
| Debt / EquityLower = less leverage | 0.12× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | $104.9M | ||
| Q3 25 | $93.4M | $108.2M | ||
| Q2 25 | $95.7M | $118.2M | ||
| Q1 25 | $98.0M | $117.4M | ||
| Q4 24 | $125.3M | $135.5M | ||
| Q3 24 | $152.6M | $128.8M | ||
| Q2 24 | $164.9M | $142.0M | ||
| Q1 24 | $167.2M | $155.7M |
| Q4 25 | $778.2M | $133.4M | ||
| Q3 25 | $778.0M | $136.5M | ||
| Q2 25 | $776.3M | $142.6M | ||
| Q1 25 | $839.4M | $136.7M | ||
| Q4 24 | $828.5M | $135.6M | ||
| Q3 24 | $1.2B | $179.3M | ||
| Q2 24 | $1.2B | $169.6M | ||
| Q1 24 | $1.2B | $175.5M |
| Q4 25 | $1.1B | $391.7M | ||
| Q3 25 | $1.1B | $400.3M | ||
| Q2 25 | $1.0B | $429.8M | ||
| Q1 25 | $1.1B | $419.8M | ||
| Q4 24 | $1.2B | $424.6M | ||
| Q3 24 | $1.7B | $495.3M | ||
| Q2 24 | $1.7B | $503.2M | ||
| Q1 24 | $1.7B | $509.2M |
| Q4 25 | 0.12× | 0.79× | ||
| Q3 25 | 0.12× | 0.79× | ||
| Q2 25 | 0.12× | 0.83× | ||
| Q1 25 | 0.12× | 0.86× | ||
| Q4 24 | 0.15× | 1.00× | ||
| Q3 24 | 0.12× | 0.72× | ||
| Q2 24 | 0.13× | 0.84× | ||
| Q1 24 | 0.14× | 0.89× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $12.3M |
| Free Cash FlowOCF − Capex | $21.3M | $8.7M |
| FCF MarginFCF / Revenue | 11.8% | 5.6% |
| Capex IntensityCapex / Revenue | 3.8% | 2.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $34.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $12.3M | ||
| Q3 25 | $14.0M | $-1.7M | ||
| Q2 25 | $6.8M | $18.9M | ||
| Q1 25 | $25.7M | $15.2M | ||
| Q4 24 | $57.9M | $-26.6M | ||
| Q3 24 | $23.0M | $-17.1M | ||
| Q2 24 | $27.8M | $12.6M | ||
| Q1 24 | $-8.0M | $-2.4M |
| Q4 25 | $21.3M | $8.7M | ||
| Q3 25 | $7.0M | $-3.5M | ||
| Q2 25 | $-4.2M | $17.4M | ||
| Q1 25 | $19.0M | $11.4M | ||
| Q4 24 | $53.1M | $-30.6M | ||
| Q3 24 | $20.0M | $-20.3M | ||
| Q2 24 | $21.9M | $6.4M | ||
| Q1 24 | $-12.1M | $-7.4M |
| Q4 25 | 11.8% | 5.6% | ||
| Q3 25 | 3.9% | -2.3% | ||
| Q2 25 | -2.4% | 10.1% | ||
| Q1 25 | 11.3% | 6.7% | ||
| Q4 24 | 29.6% | -18.7% | ||
| Q3 24 | 11.7% | -11.8% | ||
| Q2 24 | 12.8% | 3.3% | ||
| Q1 24 | -7.3% | -3.8% |
| Q4 25 | 3.8% | 2.3% | ||
| Q3 25 | 3.9% | 1.2% | ||
| Q2 25 | 6.3% | 0.9% | ||
| Q1 25 | 4.0% | 2.2% | ||
| Q4 24 | 2.7% | 2.4% | ||
| Q3 24 | 1.8% | 1.9% | ||
| Q2 24 | 3.4% | 3.2% | ||
| Q1 24 | 2.5% | 2.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | -1.79× | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | -0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CVGI
| Global Seating | $70.7M | 46% |
| Global Electrical Systems | $49.7M | 32% |
| Trim Systems And Components | $34.4M | 22% |
